Farnesoid X receptor in chronic liver diseases: an immunohistochemical study.

Q2 Health Professions

Journal of immunoassay & immunochemistry Pub Date : 2023-11-02 Epub Date: 2023-09-04 DOI:10.1080/15321819.2023.2242920

Dina Sweed, Nanis Shawky Holah, Esraa Karman, Nancy Asaad, Shereen Mahmoud

{"title":"Farnesoid X receptor in chronic liver diseases: an immunohistochemical study.","authors":"Dina Sweed, Nanis Shawky Holah, Esraa Karman, Nancy Asaad, Shereen Mahmoud","doi":"10.1080/15321819.2023.2242920","DOIUrl":null,"url":null,"abstract":"Chronic hepatitis C virus (HCV) related liver diseases are still an ongoing cause of hepatic failure despite the effective role of direct-acting anti-viral agents. Farnesoid X receptor (FXR) agonists have a potential therapeutic effect on the management of chronic liver diseases (CLD). However, data regarding FXR protein expression in human CLDs are limited and conflicting. We aimed to assess the immunohistochemical expression of FXR in HCV-related chronic hepatitis and cirrhosis in comparison with metabolic-associated fatty liver disease (MAFLD) and normal liver tissue. The expression of FXR was low both in hepatocytes and bile ducts of HCV-related chronic hepatitis and cirrhosis (p = .001, respectively). In addition, a significantly low expression of FXR was observed in HCV-related hepatitis and cirrhosis groups compared to MAFLD in hepatocytes (p < .001, for both) and bile ducts (p = .004 and p = .018). FXR expression in HCV-related cirrhosis was significantly associated with compensated liver function (p = .032) and low inflammatory activity (p = .022). FXR expression decreases in HCV-related CLDs. There was some evidence that FXR expression could protect against post-hepatitis cirrhosis.","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"381-395"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of immunoassay & immunochemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15321819.2023.2242920","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Health Professions","Score":null,"Total":0}

引用次数: 0

Abstract

Chronic hepatitis C virus (HCV) related liver diseases are still an ongoing cause of hepatic failure despite the effective role of direct-acting anti-viral agents. Farnesoid X receptor (FXR) agonists have a potential therapeutic effect on the management of chronic liver diseases (CLD). However, data regarding FXR protein expression in human CLDs are limited and conflicting. We aimed to assess the immunohistochemical expression of FXR in HCV-related chronic hepatitis and cirrhosis in comparison with metabolic-associated fatty liver disease (MAFLD) and normal liver tissue. The expression of FXR was low both in hepatocytes and bile ducts of HCV-related chronic hepatitis and cirrhosis (p = .001, respectively). In addition, a significantly low expression of FXR was observed in HCV-related hepatitis and cirrhosis groups compared to MAFLD in hepatocytes (p < .001, for both) and bile ducts (p = .004 and p = .018). FXR expression in HCV-related cirrhosis was significantly associated with compensated liver function (p = .032) and low inflammatory activity (p = .022). FXR expression decreases in HCV-related CLDs. There was some evidence that FXR expression could protect against post-hepatitis cirrhosis.

查看原文本刊更多论文

Farnesoid X受体在慢性肝病中的免疫组化研究。

尽管有直接作用的抗病毒药物的有效作用，但与丙型肝炎病毒（HCV）相关的慢性肝病仍然是肝衰竭的持续原因。法尼糖样X受体（FXR）激动剂对慢性肝病（CLD）的治疗具有潜在的治疗作用。然而，关于人类CLD中FXR蛋白表达的数据是有限的，并且相互矛盾。我们的目的是评估FXR在HCV相关慢性肝炎和肝硬化中的免疫组织化学表达，并与代谢相关脂肪肝（MAFLD）和正常肝组织进行比较。与HCV相关的慢性肝炎和肝硬化的肝细胞和胆管中FXR的表达均较低（p = .001）。此外，与肝细胞中的MAFLD相比，在HCV相关肝炎和肝硬化组中观察到FXR的表达显著较低（p p = .004和p = .018）。FXR在HCV相关肝硬化中的表达与代偿性肝功能显著相关（p = .032）和低炎症活性（p = .022）。FXR在HCV相关CLD中的表达降低。有证据表明FXR的表达可以预防肝炎后肝硬化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of immunoassay & immunochemistry 医学-免疫学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal of Immunoassay & Immunochemistry is an international forum for rapid dissemination of research results and methodologies dealing with all aspects of immunoassay and immunochemistry, as well as selected aspects of immunology. They include receptor assay, enzyme-linked immunosorbent assay (ELISA) in all of its embodiments, ligand-based assays, biological markers of ligand-receptor interaction, in vivo and in vitro diagnostic reagents and techniques, diagnosis of AIDS, point-of-care testing, clinical immunology, antibody isolation and purification, and others.